(Reuters) – China has suspended the sale, import and use of the cancer drug from Bristol-Myers Squibb Co, Abraxane, the Chinese drugmaker’s trading partner said on Wednesday.
The suspension by the China National Medical Products Administration is based on the results of an inspection at the Bristol-Myers contract manufacturing plant in the United States, said partner Beigene Ltd.
Beigene and Bristol-Myers were working to restore supply as soon as possible, said the Chinese-based drug manufacturer, which signed an agreement with the Celgene unit at Bristol-Myers in 2017 to market and distribute Abraxane.
In addition to remediation efforts, Bristol-Myers has sought approval to source Abraxane for the Chinese market from an alternative manufacturing facility, said Beigene.
Manas Mishra reports to Bengaluru; Editing by Vinay Dwivedi and Shinjini Ganguli
Our standards:Principles of the Thomson Reuters Trust.